AU2022297426A1 - Therapeutic compounds - Google Patents

Therapeutic compounds Download PDF

Info

Publication number
AU2022297426A1
AU2022297426A1 AU2022297426A AU2022297426A AU2022297426A1 AU 2022297426 A1 AU2022297426 A1 AU 2022297426A1 AU 2022297426 A AU2022297426 A AU 2022297426A AU 2022297426 A AU2022297426 A AU 2022297426A AU 2022297426 A1 AU2022297426 A1 AU 2022297426A1
Authority
AU
Australia
Prior art keywords
therapeutic compounds
therapeutic
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022297426A
Other languages
English (en)
Inventor
Pratik DATTA
Ajit K. Parhi
Jesus ROSADO
Yi Yuan
Yongzheng Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TAXIS PHARMACEUTICALS Inc
Original Assignee
TAXIS PHARMACEUTICALS Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TAXIS PHARMACEUTICALS Inc filed Critical TAXIS PHARMACEUTICALS Inc
Publication of AU2022297426A1 publication Critical patent/AU2022297426A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2022297426A 2021-06-22 2022-06-21 Therapeutic compounds Pending AU2022297426A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163213519P 2021-06-22 2021-06-22
US63/213,519 2021-06-22
PCT/US2022/034374 WO2022271723A1 (en) 2021-06-22 2022-06-21 Therapeutic compounds

Publications (1)

Publication Number Publication Date
AU2022297426A1 true AU2022297426A1 (en) 2024-02-01

Family

ID=84544904

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022297426A Pending AU2022297426A1 (en) 2021-06-22 2022-06-21 Therapeutic compounds

Country Status (10)

Country Link
US (1) US20240317749A1 (cg-RX-API-DMAC7.html)
EP (1) EP4359416A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024524213A (cg-RX-API-DMAC7.html)
KR (1) KR20240067229A (cg-RX-API-DMAC7.html)
CN (1) CN118251394A (cg-RX-API-DMAC7.html)
AU (1) AU2022297426A1 (cg-RX-API-DMAC7.html)
CA (1) CA3225427A1 (cg-RX-API-DMAC7.html)
IL (1) IL309569A (cg-RX-API-DMAC7.html)
MX (1) MX2024000022A (cg-RX-API-DMAC7.html)
WO (1) WO2022271723A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117815240A (zh) * 2023-12-11 2024-04-05 兰州大学 一类具有二氨基吡咯并喹唑啉结构的化合物在防治奶牛乳腺炎致病菌中的用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2436524T3 (es) * 2003-05-22 2014-01-02 Nerviano Medical Sciences S.R.L. Derivados de pirazolo-quinazolina, procedimiento para su preparación y su uso como inhibidores de cinasas
US8673929B2 (en) * 2006-07-20 2014-03-18 Gilead Sciences, Inc. 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives and pharmaceutical compositions useful for treating viral infections
US20090227575A1 (en) * 2008-03-04 2009-09-10 Wyeth 7H-PYRROLO[2,3-H]QUINAZOLINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESIS
BR112013008527A2 (pt) * 2010-12-17 2016-07-12 Nerviano Medical Sciences Srl derivados de pirazolo-quinazolina substituídos como inibidores de cinase
US12428423B2 (en) * 2017-04-01 2025-09-30 Shengke Pharmaceuticals (Jiangsu) Ltd. 1H-imidazo[4,5-h]quinazoline compound as protein kinase inhibitor
US11077109B2 (en) * 2017-08-01 2021-08-03 The Trustees Of Princeton University Compounds having antibacterial activity and methods of use
KR102464677B1 (ko) * 2017-08-11 2022-11-10 셍커 파마슈티컬스 (지앙수) 엘티디. 단백질 인산화효소 억제제로 작용하는 1h-피라졸로[4,3-h]퀴나졸린 화합물
CN119455003A (zh) * 2019-02-12 2025-02-18 Ambrx公司 包含抗体-tlr激动剂缀合物的组合物、方法和用途
WO2022040596A1 (en) * 2020-08-20 2022-02-24 Ambrx, Inc. Antibody-tlr agonist conjugates, methods and uses thereof
EP4204093A1 (en) * 2020-08-27 2023-07-05 Shengke Pharmaceuticals (Jiangsu) Ltd. 1h-imidazo [4,5-h] quinazoline compound as novel selective flt3 inhibitors

Also Published As

Publication number Publication date
WO2022271723A1 (en) 2022-12-29
EP4359416A1 (en) 2024-05-01
MX2024000022A (es) 2024-03-15
JP2024524213A (ja) 2024-07-05
US20240317749A1 (en) 2024-09-26
CA3225427A1 (en) 2022-12-29
IL309569A (en) 2024-02-01
CN118251394A (zh) 2024-06-25
KR20240067229A (ko) 2024-05-16
EP4359416A4 (en) 2025-05-14

Similar Documents

Publication Publication Date Title
EP4380936A4 (en) PYRAZOLOPYRIDINONE COMPOUNDS
GB202005852D0 (en) Therapeutic compounds
GB202103640D0 (en) Therapeutic compounds
CA3266672A1 (en) POLYTHERAPY
CA3261397A1 (en) POLYTHERAPY
GB202005863D0 (en) Therapeutic compounds
EP3999052A4 (en) IMMUNO-ONCOLOGICAL THERAPY USING ISOFLAVONE COMPOUNDS
GB202103642D0 (en) Therapeutic compounds
HK40130315A (en) Therapeutic compounds
CA3276216A1 (en) Therapeutic compounds
HK40082055A (en) Therapeutic compounds
HK40105578A (en) Therapeutic methods
CA3291458A1 (en) Therapy
HK40101542A (en) Combination therapy
CA3271207A1 (en) Therapy
AU2021903021A0 (en) Combination Therapy
AU2021900742A0 (en) Combination therapy
AU2021900459A0 (en) Combination therapy
HK40119156A (en) Compounds
HK40118327A (en) Compounds
HK40111953A (en) Compounds
HK40119138A (en) Compounds
HK40117069A (en) Rabeximod compounds
HK40117622A (en) Compounds
HK40111694A (en) Pyrazolopyridinone compounds